Insider Buying: VolitionRx Limited (NYSE:VNRX) CEO Purchases 78,125 Shares of Stock

Key Points

• CEO Cameron John Reynolds purchased 78,125 shares of VolitionRx Limited at an average price of $0.64 per share, totaling approximately $50,000.
• The company's stock has a market capitalization of $67.59 million and has recently traded slightly up, reaching $0.65 per share.
• Analysts have issued mixed ratings for VolitionRx, with a consensus price target of $3.50 and varying recommendations ranging from sell to strong buy.

VolitionRx Limited (NYSE:VNRX - Get Free Report) CEO Cameron John Reynolds acquired 78,125 shares of the company's stock in a transaction dated Tuesday, August 5th. The shares were acquired at an average cost of $0.64 per share, with a total value of $50,000.00. Following the completion of the purchase, the chief executive officer owned 2,609,847 shares in the company, valued at approximately $1,670,302.08. This represents a 3.09% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Cameron John Reynolds also recently made the following trade(s):

• On Thursday, June 12th, Cameron John Reynolds acquired 12,500 shares of VolitionRx stock. The shares were acquired at an average cost of $0.59 per share, with a total value of $7,375.00.
• On Monday, May 19th, Cameron John Reynolds bought 20,000 shares of VolitionRx stock. The shares were purchased at an average price of $0.44 per share, for a total transaction of $8,800.00.

VolitionRx Trading Down 1.4%

VNRX stock traded down $0.01 during trading on Friday, reaching $0.63. The stock had a trading volume of 13,289 shares, compared to its average volume of 195,028. The firm has a fifty day moving average price of $0.69 and a 200 day moving average price of $0.59. The company has a market capitalization of $65.51 million, a P/E ratio of -1.74 and a beta of 1.26. VolitionRx Limited has a 1-year low of $0.40 and a 1-year high of $0.94.

Institutional Investors Weigh In On VolitionRx

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Securities LLC bought a new stake in shares of VolitionRx during the 4th quarter valued at about $29,000. Northern Trust Corp lifted its stake in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after purchasing an additional 28,579 shares during the last quarter. Lagoda Investment Management L.P. lifted its stake in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after purchasing an additional 1,481,000 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of VolitionRx during the fourth quarter valued at approximately $36,000. Finally, Silverberg Bernstein Capital Management LLC raised its holdings in shares of VolitionRx by 42.8% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock valued at $153,000 after acquiring an additional 60,209 shares during the period. Institutional investors own 8.09% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Wall Street Zen began coverage on shares of VolitionRx in a report on Thursday, May 15th. They issued a "sell" rating on the stock. D. Boral Capital restated a "buy" rating and set a $5.00 target price on shares of VolitionRx in a report on Thursday, July 17th. Finally, Jones Trading upgraded shares of VolitionRx to a "strong-buy" rating and set a $3.00 target price on the stock in a report on Tuesday, June 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $3.50.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.